• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Artiva Biotherapeutics Inc.

    8/6/25 4:19:41 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ARTV alert in real time by email
    S-8 1 artv-20250806.htm S-8 S-8

     

     

    As filed with the Securities and Exchange Commission on August 6, 2025

    Registration No. 333- 

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    Artiva Biotherapeutics, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware

    (State or other jurisdiction of

    incorporation or organization)

    83-3614316

    (I.R.S. Employer

    Identification No.)

    5505 Morehouse Drive, Suite 100

    San Diego, CA

    (Address of Principal Executive Offices)

    92121

    (Zip Code)

     

    Artiva Biotherapeutics, Inc. 2024 Equity Incentive Plan

    Artiva Biotherapeutics, Inc. 2024 Employee Stock Purchase Plan

    (Full titles of the plans)

    Fred Aslan, M.D.

    President and Chief Executive Officer

    Artiva Biotherapeutics, Inc.

    5505 Morehouse Drive, Suite 100

    San Diego, CA 92121

    (858) 267-4467

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

    Copies to:

    Carlos Ramirez

    Cooley LLP

    10265 Science Center Drive

    San Diego, CA 92121

    (858) 550-6000

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large Accelerated filer 

    Accelerated filer 

    Non-accelerated filer 

    Smaller reporting company 

     

    Emerging growth company 

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.☐

     


     

    EXPLANATORY NOTE

    This Registration Statement on Form S-8 (this “Registration Statement”) is being filed by Artiva Biotherapeutics, Inc. (the “Registrant”) with the Securities and Exchange Commission (the “Commission”) for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement on Form S-8 relating to the same employee benefit plans is effective. The Registrant previously registered its shares of common stock, par value $0.0001 per share, for issuance under the Registrant’s 2024 Equity Incentive Plan and the Registrant’s 2024 Employee Stock Purchase Plan under the Registrant's Registration Statement on Form S-8 (the “Prior Registration Statement”) filed with the SEC on July 22, 2024 (File No. 333-280950).

    PART II

    ITEM 3. INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE

    The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:

    (a) The Registrant’s Current Reports on Form 8-K filed with the Commission on January 29, 2025 and June 25, 2025 (File No. 001-42179) (each to the extent the information in such reports is filed and not furnished);

    (b) The Registrant’s Quarterly Reports on Form 10-Q filed with the Commission for the quarters ended March 31, 2025 and June 30, 2025, on May 8, 2025 and August 6, 2025, respectively (File No. 001-42179);

    (c) The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 24, 2025 (File No. 001-42179);

    (d) The information specifically incorporated by reference into the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 from the Registrant’s Definitive Proxy Statement on Schedule 14A (other than information furnished rather than filed), filed with the Commission on April 29, 2025 (File No. 001-42179); and

    (e) The description of the Registrant’s Common Stock contained in the Registrant’s Registration Statement on Form 8-A12B filed on July 16, 2024 (File No. 001-42179) under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report filed for the purpose of updating such description, including Exhibit 4.3 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 24, 2025 (File No. 001-39979).

    All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement

    Item 8. Exhibits.

    The exhibits to this Registration Statement are listed below:

     


     

    Exhibit
    Number

    Description

    4.1

    Amended and Restated Certificate of Incorporation, as currently in effect (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-42179, filed with the Commission on July 22, 2024).

    4.2

    Amended and Restated Bylaws, as currently in effect (incorporated herein by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-42179, filed with the Commission on July 22, 2024).

    4.3

    Form of Common Stock Certificate (incorporated herein by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-280568), filed with the Commission on June 28, 2024).

    4.4

    Amended and Restated Investors’ Rights Agreement, dated February 22, 2021, by and among the Registrant and certain of its stockholders (incorporated herein by reference to Exhibit 4.2 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-280568), filed with the Commission on June 28, 2024).

    5.1*

    Opinion of Cooley LLP.

    23.1*

    Consent of Independent Registered Public Accounting Firm.

    23.2*

    Consent of Cooley LLP (included in Exhibit 5.1).

    24.1*

    Power of Attorney (included on signature page).

    99.1

    2024 Equity Incentive Plan, as amended (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-42179) filed with the SEC on June 25, 2025.

    99.2

    Form of Stock Option Grant Notice, Option Agreement and Notice of Exercise under the 2024 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.5 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-280568), filed with the Commission on June 28, 2024).

    99.3

    Form of Restricted Stock Unit Grant Notice and Award Agreement under the 2024 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.6 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-280568), filed with the Commission on July 15, 2024).

    99.4

    2024 Employee Stock Purchase Plan (incorporated herein by reference to Exhibit 99.6 to the Registrant’s Registration Statement on Form S-8 (File No. 333-280950), filed with the Commission on July 22, 2024).

    107*

    Filing Fee Disclosure and Payment Methods.

     

    * Filed herewith.

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on August 6, 2025.

    ARTIVA BIOTHERAPEUTICS, INC.

     

     

    By:

     

    /s/ Fred Aslan, M.D.

     

     

    Fred Aslan, M.D.

     

     

    President and Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Fred Aslan, M.D. and Neha Krishnamohan and each of them, as his or her true and lawful attorneys-in-fact and agents, and each of them, with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

    Signature

     

    Title

     

    Date

     

     

     

    /s/ Fred Aslan, M.D.

    Fred Aslan, M.D.

     

    President, Chief Executive Officer and Director

    (Principal Executive Officer)

     

    August 6, 2025

     

     

     

    /s/ Neha Krishnamohan

    Neha Krishnamohan

     

    Chief Financial Officer and EVP, Corporate Development

    (Principal Financial and Accounting Officer)

     

    August 6, 2025

     

     

     

    /s/ Brian Daniels, M.D.

    Brian Daniels, M.D.

     

    Chairperson of the Board of Directors

     

    August 6, 2025

     

     

     

    /s/ Daniel Baker, M.D.

    Daniel Baker, M.D.

     

    Director

     

    August 6, 2025

     

     

     

     

     

    /s/ Elizabeth Hougen

     

    Director

     

    August 6, 2025

    Elizabeth Hougen

     

     

     

    /s/ Diego Miralles, M.D.

    Diego Miralles, M.D.

     

    Director

     

    August 6, 2025

     

     

     

    /s/ Alison Moore

     

    Director

     

    August 6, 2025

    Alison Moore

     

     

     

     

     

     

     

     

     

    /s/ Laura Stoppel, Ph.D.

    Laura Stoppel, Ph.D.

     

    Director

     

    August 6, 2025

     

     


    Get the next $ARTV alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARTV

    DatePrice TargetRatingAnalyst
    6/11/2025$12.00Buy
    H.C. Wainwright
    12/30/2024$20.00Buy
    H.C. Wainwright
    8/13/2024$21.00Buy
    Jefferies
    8/13/2024$23.00Overweight
    Cantor Fitzgerald
    8/13/2024Buy
    TD Cowen
    8/13/2024$18.00Outperform
    Wedbush
    8/13/2024$23.00Buy
    Needham
    More analyst ratings

    $ARTV
    SEC Filings

    View All

    SEC Form EFFECT filed by Artiva Biotherapeutics Inc.

    EFFECT - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

    8/18/25 12:15:21 AM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-3 filed by Artiva Biotherapeutics Inc.

    S-3 - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

    8/6/25 5:16:00 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 filed by Artiva Biotherapeutics Inc.

    S-8 - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

    8/6/25 4:19:41 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARTV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Artiva Biotherapeutics with a new price target

    H.C. Wainwright resumed coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $12.00

    6/11/25 7:52:47 AM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Artiva Biotherapeutics with a new price target

    H.C. Wainwright initiated coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $20.00

    12/30/24 7:13:58 AM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jefferies initiated coverage on Artiva Biotherapeutics with a new price target

    Jefferies initiated coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $21.00

    8/13/24 7:24:03 AM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARTV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ra Capital Management, L.P. converted options into 1,058,282 shares, acquired $4,709,207 worth of shares (461,687 units at $10.20) and bought $99,999,996 worth of shares (8,333,333 units at $12.00) (SEC Form 4)

    4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

    7/24/24 4:27:11 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner 5am Partners Vi, Llc converted options into 1,058,284 shares, acquired $4,709,207 worth of shares (461,687 units at $10.20) and bought $9,999,996 worth of shares (833,333 units at $12.00) (SEC Form 4)

    4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

    7/24/24 4:15:09 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Venbio Global Strategic Fund Iii, L.P. bought $4,999,992 worth of shares (416,666 units at $12.00), converted options into 1,058,284 shares and acquired 461,687 shares (SEC Form 4)

    4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

    7/22/24 8:26:49 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARTV
    Leadership Updates

    Live Leadership Updates

    View All

    Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights

    IND clearance and initiation of global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren's disease, idiopathic inflammatory myopathies and systemic sclerosis First trial to explore an allogeneic cell therapy in refractory rheumatoid arthritis and Sjögren's disease in the U.S. Initial safety, translational data, and lead indication selection to be presented by year-end 2025; initial clinical response data in the lead indication to be presented in 1H2026 Longer-term clinical data from Phase 1/2 trial exploring AlloNK + rituximab in B-NHL in heavily pretreated CAR-T naïve patients to be presented at ASGCT, demonstrating complete response rates and

    5/8/25 8:00:00 AM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer

    SAN DIEGO, April 08, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Subhashis Banerjee, M.D., as Chief Medical Officer. Dr. Banerjee is a trained rheumatologist and immunologist who brings over two decades of clinical development experience in autoimmune diseases, most recently as Disease Area Head for Rheumatology and Dermatology Global Development at Bristol Myers Squibb (BMS), and Senior Vice President (SVP), Clinical Development at VYNE Therapeutics, Inc.

    4/8/25 4:05:00 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D.

    SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Dan Baker, M.D., as an independent member of its Board of Directors. Dr. Baker brings over two decades of drug development experience in the pharmaceutical industry. He is currently the interim Chief Development Officer of Cue Biopharma, Inc., and previously held a 19-year tenure at Johnson & Johnson (Janssen/Centocor) (J & J) most recently as the Vice President of Immunology R&D. "Dan is a ph

    1/29/25 4:05:00 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARTV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Artiva Biotherapeutics Inc.

    SC 13G/A - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

    11/14/24 4:56:18 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Artiva Biotherapeutics Inc.

    SC 13D/A - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

    9/3/24 4:18:05 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Artiva Biotherapeutics Inc.

    SC 13G - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

    8/1/24 7:00:07 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARTV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights

    First patient treated in company-sponsored global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren's disease, idiopathic inflammatory myopathies, and systemic sclerosis Continued execution and enrollment progress with over a dozen patients treated with AlloNK + mAb across over a dozen sites in company-sponsored and investigator-initiated clinical trials in autoimmune diseases Initial safety, translational data, and lead indication selection for AlloNK in autoimmune diseases to be presented by year-end 2025; initial clinical response data in the lead indication to be presented in 1H2026 Cash runway into Q2 2027, with cash, cash equivalents, and i

    8/6/25 4:05:00 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ArrePath Announces Closing of Their Next Financing Round and Appointment of a New Board Chair

    ArrePath, a company applying its proprietary artificial intelligence and machine learning platform together with deep R&D technical expertise to address the challenge of best-in-class antibacterial drug discovery, announced several business updates. First, the company has raised the next round of financing to advance its pipeline and continue to expand the scope and capabilities of its discovery platform. The Boehringer Ingelheim Venture Fund led the financing, which also included existing investors Insight Partners, Innospark, and Nor'easter Ventures, and new investor AB Magnitude. "We are grateful for the ongoing support of our strong investor base and welcome our new investor, AB Magni

    6/23/25 8:45:00 PM ET
    $ARTV
    $CTNM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference

    SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, announced today that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 9:20 a.m. EDT. Members of the Artiva management team will also be available to participate in investor meetings with investors who are registered to attend the conference. Investors and the general public are invited to listen to a live webcast of the presentation through the "Investor

    5/28/25 4:05:00 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARTV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Krishnamohan Neha covered exercise/tax liability with 7,154 shares, decreasing direct ownership by 7% to 102,846 units (SEC Form 4)

    4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

    8/18/25 8:15:10 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Aslan Fred covered exercise/tax liability with 8,944 shares and sold $69,579 worth of shares (25,500 units at $2.73), decreasing direct ownership by 8% to 382,221 units (SEC Form 4)

    4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

    8/18/25 8:15:13 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SVP, Research and Development Raymon Heather covered exercise/tax liability with 2,384 shares, decreasing direct ownership by 5% to 40,966 units (SEC Form 4)

    4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

    8/18/25 8:15:11 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care